This is Exchanges at Goldman Sachs where we discuss development shaping industries, markets, and the global economy.

I'm Allison Nathan, a senior strategist in Goldman Sachs research.

Today we're going to talk about gene editing, which is an emerging and in the words of our analysts

transformative biotechnology on the verge of rapid growth

that has the potential to cure genetic diseases.

A wave of innovation and M&A activity in the space is capturing investor attention.

So I've asked Selveine Richter, our lead biotechnology research analyst in the U.S.

To join us to walk through the latest developments, the most promising applications, and the outlook for broader

adoption. Salveen, welcome to the program.

Allison, thanks for having me.

So let's start with the basics.

For those who aren't as familiar with the space, what exactly is gene

editing? So gene editing is a versatile tool and it's capable of making permanent

precise edits to the human genome.

So I would think of it as a molecular scissors that really works to provide functional cures,

and the spectrum of these different types of edits that can be made are growing as the technology

evolves here. It is a revolutionary technology as you mentioned and we really do

think it's poised to move the era of genomic medicine forward.

There's an increasing focus here on evaluating the next frontiers in biotechnology,

and we do view this as poised for rapid growth.

And how does it differ from the related field of gene therapy?

The technology itself has the ability to address some of the challenges that are

...